Holen Sie sich die Stockscreener-App
3.63
3.20%
-0.12
Vorhandelsmarkt:
3.87
0.24
+6.61%
Nrx Pharmaceuticals Inc Aktie (NRXP) Neueste Nachrichten
NRX Pharmaceuticals Inc (NRXP) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
NRX Pharmaceuticals Market Sentiment - Benzinga España
NRX Pharmaceuticals Inc (NRXP) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
NRX Pharmaceuticals Inc (NRXP) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
NRX Pharmaceuticals Inc (NRXP) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
NRX Pharmaceuticals Inc (NRXP) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
NRX Pharmaceuticals Inc (NRXP) Cash Flow - TradingKey
NRXP|NRX Pharmaceuticals Inc|Price:3.620|Chg%:-0.130 - TradingKey
TradingKey - TradingKey
NRX Pharmaceuticals, Inc. Revenue Breakdown – MUN:B1Q - TradingView
NRX Pharmaceuticals, Inc. Revenue Breakdown – FWB:B1Q - TradingView
NRX Pharmaceuticals Inc (B1Q.HM) stock price, news, quote and history - Yahoo Finance UK
NRX Pharmaceuticals Inc (B1Q.HM) stock major holders - Yahoo Finance UK
NRX Pharmaceuticals Inc (NRXP) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
NRx Pharmaceuticals Selected by DARPA for Innovative SPARC-TMS Clinical Trial to Treat Depression - Minichart
Market Sentiment Around Loss-Making NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) - Sahm
NRXP Stock Price, Quote & Chart - ChartMill
Is NRx Pharmaceuticals, Inc. (NRXP) Stock Positioned for Growth Through Depression and PTSD Treatment Innovation? - Yahoo Finance
NRX Pharmaceuticals Inc (NRXPW) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Equity in earnings of NRX Pharmaceuticals, Inc. – DUS:B1Q - TradingView
Enterprise value to revenue forward of NRX Pharmaceuticals, Inc. – NASDAQ:NRXP - TradingView
NRXP Should I Buy - Intellectia AI
First Patients Treated via FDA-Cleared Transcranial Magnetic Stimulation, Plus FDA Grant on D-Cycloserine-Based Drug for Depression: NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) - Barchart.com
NRx Pharmaceuticals, Inc.(NasdaqCM:NRXP) dropped from Russell 3000E Growth Benchmark - marketscreener.com
NRx Pharmaceuticals, Inc.(NasdaqCM:NRXP) dropped from Russell Microcap Growth Benchmark Index - marketscreener.com
Price to book forward of NRX Pharmaceuticals, Inc. – NASDAQ:NRXP - TradingView
Price to book forward of NRX Pharmaceuticals, Inc. – DUS:B1Q - TradingView
Price to sales forward of NRX Pharmaceuticals, Inc. – NASDAQ:NRXP - TradingView
Enterprise value to revenue forward of NRX Pharmaceuticals, Inc. – DUS:B1Q - TradingView
Price to sales forward of NRX Pharmaceuticals, Inc. – DUS:B1Q - TradingView
Enterprise value to EBITDA forward of NRX Pharmaceuticals, Inc. – NASDAQ:NRXP - TradingView
Price to earnings forward of NRX Pharmaceuticals, Inc. – NASDAQ:NRXP - TradingView
Enterprise value to EBIT forward of NRX Pharmaceuticals, Inc. – NASDAQ:NRXP - TradingView
Enterprise value to EBIT forward of NRX Pharmaceuticals, Inc. – DUS:B1Q - TradingView
Price to earnings forward of NRX Pharmaceuticals, Inc. – DUS:B1Q - TradingView
NRX Pharmaceuticals(NRXP) Stock Options Chain | Quotes & News - Moomoo
H.C. Wainwright Keeps Their Buy Rating on NRX Pharmaceuticals (NRXP) - The Globe and Mail
NRx Pharmaceuticals Subsidiary HOPE Therapeutics Treats First Patients Using Zeta Surgical's FDA-Cleared Zeta TMS Navigation System - marketscreener.com
symbol__ Stock Quote Price and Forecast - CNN
NRx Pharmaceuticals Responds to Recent Public Statements Regarding Kadima Dispute - The Manila Times
NRX Pharmaceuticals, Inc. Actuals & Estimates (NASDAQ:NRXP) - TradingView
NRx Pharmaceuticals responds to Kadima dispute claims - Investing.com UK
NRx Pharmaceuticals responds to Kadima dispute claims By Investing.com - Investing.com South Africa
NRx subsidiary begins AI-guided TMS treatments in Florida - Investing.com UK
NRXP Forecast — Price Target — Prediction for 2027 - TradingView
NRx Pharmaceuticals (Nasdaq: NRXP) Subsidiary HOPE Therapeutics Treats First Patients Using Zeta Surgical's FDA-Cleared Zeta TMS Navigation System - GlobeNewswire
Kadima sues NRx Pharmaceuticals over failed acquisition deal - Investing.com UK
Kadima Neuropsychiatry Institute Sues NRX Pharmaceuticals Over Breach of Acquisition Contract - marketscreener.com
Kadima sues NRx Pharmaceuticals over failed acquisition deal By Investing.com - Investing.com South Africa
Kadima Neuropsychiatry Institute Files Suit Against NRx Pharmaceuticals (NASDAQ: NRXP), Alleging Breach of Contract and Misrepresentation in Connection with Acquisition - Business Wire
NRx Pharmaceuticals, Inc. (NRXP) reports Q1 loss, lags revenue estimates - MSN
ZETA SURGICAL® Announces Successful Treatment of First Patient with Zeta TMS Navigation System at HOPE Therapeutics - Sahm
BTIG Maintains NRX Pharmaceuticals(NRXP.US) With Buy Rating, Maintains Target Price $25 - Moomoo
EBIT per share of NRX Pharmaceuticals, Inc. – DUS:B1Q - TradingView
Cash per share of NRX Pharmaceuticals, Inc. – DUS:B1Q - TradingView
1.97%
0.83%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):